Is PSYENCE BIOMEDICAL LTD. (PBM) Halal?

NASDAQ Healthcare Canada $6M
✗ NOT HALAL
Confidence: 83/100
PSYENCE BIOMEDICAL LTD. (PBM) is Not Halal under AAOIFI Standard 21. While the debt ratio of 0.0% is acceptable, the cash and interest-bearing securities ratio of 213.1% exceeds the 30% threshold. PSYENCE BIOMEDICAL LTD. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from March 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.0%
/ 30%
213.1%
/ 30%
4.8%
/ 30%
N/A ✗ NOT HALAL
DJIM 0.0%
/ 33%
213.1%
/ 33%
4.8%
/ 33%
N/A ✗ NOT HALAL
MSCI 0.0%
/ 33%
83.9%
/ 33%
1.9%
/ 33%
N/A ✗ NOT HALAL
S&P 0.0%
/ 33%
213.1%
/ 33%
4.8%
/ 33%
N/A ✗ NOT HALAL
FTSE 0.0%
/ 33%
83.9%
/ 33%
1.9%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-389.98
P/B Ratio
0.1
EV/EBITDA
1.5
EV: -$6M
Revenue
$0
Beta
0.4
Low volatility
Current Ratio
8.1

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -74.3%
Return on Assets (ROA) -34.4%

Cash Flow & Balance Sheet

Operating Cash Flow-$4M
Free Cash Flow-$4M
Current Ratio8.1
Total Assets$7M

Price & Trading

Last Close$2.63
50-Day MA$3.94
200-Day MA$99.46
Avg Volume204K
Beta0.4
52-Week Range
$1.92
$468.36

About PSYENCE BIOMEDICAL LTD. (PBM)

CEO
Mr. Jody Aufrichtig
Employees
12
Sector
Healthcare
Industry
Biotechnology
Country
Canada
Exchange
NASDAQ
Market Cap
$6M
Currency
USD

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is PSYENCE BIOMEDICAL LTD. (PBM) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), PSYENCE BIOMEDICAL LTD. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is PSYENCE BIOMEDICAL LTD.'s debt ratio?

PSYENCE BIOMEDICAL LTD.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.

What are PSYENCE BIOMEDICAL LTD.'s key financial metrics?

PSYENCE BIOMEDICAL LTD. has a market capitalization of $6M. Return on equity stands at -74.3%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.